London, Jan 17, 2026, 17:05 GMT — The market has closed.
- AstraZeneca shares closed Friday at 14,052 pence, rising 0.19% following a 2.23% decline the previous day.
- Barclays maintained its Buy rating and set a target of 16,500p, according to a broker note.
- Investors are focusing on the Nasdaq-100 reshuffle set for Jan 20 and AstraZeneca’s earnings report due Feb 10.
AstraZeneca PLC shares ended Friday up 0.19%, closing at 14,052 pence (£140.52). This modest recovery followed Thursday’s 2.23% decline, which had pressured the stock heading into the weekend.
Timing is key as London stocks hover close to all-time highs, but the rally is patchy, not uniform. On Friday, the FTSE 100 edged down 0.04%, dragged lower by miners after copper prices fell, while defence shares gained ground.
Europe’s equity rally paused rather than reversed last week. “European equities aren’t cheap anymore, but they’re not expensive either. That said, the margin of safety that investors had previously is gone,” said Michael Field, chief European equity strategist at Morningstar. The STOXX 600 still notched a fifth consecutive weekly gain, despite Friday’s weaker finish. Reuters
Broker chatter around AstraZeneca remained upbeat. Barclays’ James Gordon stuck with his Buy rating and held the target price steady at 16,500 pence, according to a MarketScreener report.
A mechanical catalyst is set to hit the U.S. next week. Nasdaq announced Walmart will take AstraZeneca’s spot in the Nasdaq-100 on Jan. 20 — a switch that typically triggers buying and selling by funds tracking that index.
AstraZeneca is also reshaping its U.S. market presence. Shareholders gave the green light for a direct listing on the New York Stock Exchange, set to begin trading on Feb. 2, 2026. The company will maintain its listings in London and Stockholm.
The more significant fundamental check-in arrives a week from now. AstraZeneca is set to release its full-year and fourth-quarter earnings on Feb. 10, per the company’s investor events calendar. That date will draw closer scrutiny to launch momentum and any pipeline updates.
The near-term outlook is a double-edged sword. A misstep in trial results, an unexpected regulatory decision, or a change in drug-pricing policy could send the sector tumbling. The stock has already demonstrated its volatility, even when news is scarce.
At Monday’s London open, traders will be eyeing whether AstraZeneca extends Friday’s modest rebound or if Thursday’s decline sets up a lower-high pattern amid the deepening earnings season.
Up next: the Nasdaq-100 reshuffle on Jan. 20, AstraZeneca’s debut on the NYSE set for Feb. 2, followed by its earnings report on Feb. 10.
